{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:13:30Z","timestamp":1792098810074,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81670325"],"award-info":[{"award-number":["81670325"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Finerenone is a third-generation mineralocorticoid receptor antagonists, which has shown good cardiac function improvement in patients with type 2 diabetes in large-scale clinical trials. However, its specific role in diabetic cardiomyopathy remains unclear. We explored the potential functions and mechanisms of finerenone in diabetic cardiomyopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The type 2 diabetic rat model was induced by high-fat diet and low-dose streptozotocin (n\u2009=\u20096, each group). Next the drug group was treated with finerenone (1\u00a0mg\/kg\/day) for 8\u00a0weeks. Then we detected the cardiac structure and function and relevant indicators. Neonatal rat cardiomyocytes were used for in vitro culture to determine the direct effect of finerenone on cardiomyocytes stimulated by high glucose and high fatty acid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with the control group, rats in the type 2 diabetes group exhibited hyperglycemia, hyperlipidemia, and impaired cardiac function. Myocardium showed increased fibrosis and apoptosis. Finerenone attenuated these impairments without changing blood glucose levels. In neonatal rat cardiomyocytes, the stimulation of high concentrations of palmitic acid increased fatty acid uptake, as well as increased reactive oxygen species and apoptosis. Finerenone significantly improved fatty acid metabolism, reduced cellular inflammation levels, and decreased apoptosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>By blocking the mineralocorticoid receptor, finerenone attenuates cardiac steatosis, myocardial fibrosis and apoptosis, and subsequent myocardial remodeling and diastolic dysfunction in type II diabetic rats.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-023-01064-3","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T01:01:41Z","timestamp":1682730101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus"],"prefix":"10.1186","volume":"15","author":[{"given":"Tao","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengshuang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"key":"1064_CR1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"1064_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","volume":"30","author":"S Rubler","year":"1972","unstructured":"Rubler S, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30(6):595\u2013602.","journal-title":"Am J Cardiol"},{"issue":"9","key":"1064_CR3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.amjmed.2008.03.046","volume":"121","author":"A Aneja","year":"2008","unstructured":"Aneja A, et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008;121(9):748\u201357.","journal-title":"Am J Med"},{"issue":"24","key":"1064_CR4","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1161\/CIRCULATIONAHA.110.955542","volume":"122","author":"AC Ng","year":"2010","unstructured":"Ng AC, et al. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation. 2010;122(24):2538\u201344.","journal-title":"Circulation"},{"issue":"2","key":"1064_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cmet.2020.06.002","volume":"32","author":"X Cheng","year":"2020","unstructured":"Cheng X, et al. Targeting DGAT1 ameliorates glioblastoma by increasing fat catabolism and oxidative stress. Cell Metab. 2020;32(2):229-242.e8.","journal-title":"Cell Metab"},{"issue":"7","key":"1064_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","volume":"6","author":"M Packer","year":"2018","unstructured":"Packer M, et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018;6(7):547\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1064_CR7","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1111\/j.1523-1755.2004.00524.x","volume":"65","author":"NK Hollenberg","year":"2004","unstructured":"Hollenberg NK, et al. Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int. 2004;65(4):1435\u20139.","journal-title":"Kidney Int"},{"issue":"1\u20132","key":"1064_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1023\/B:MCBI.0000028765.89855.73","volume":"261","author":"J Machackova","year":"2004","unstructured":"Machackova J, et al. Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes. Mol Cell Biochem. 2004;261(1\u20132):271\u20138.","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"1064_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2741\/3697","volume":"16","author":"R Dooley","year":"2011","unstructured":"Dooley R, Harvey BJ, Thomas W. The regulation of cell growth and survival by aldosterone. Front Biosci (Landmark Ed). 2011;16(2):440\u201357.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"8","key":"1064_CR10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L Barfacker","year":"2012","unstructured":"Barfacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385\u2013403.","journal-title":"ChemMedChem"},{"issue":"6","key":"1064_CR11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"issue":"6","key":"1064_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","volume":"143","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143(6):540\u201352.","journal-title":"Circulation"},{"issue":"4","key":"1064_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/jdi.12235","volume":"5","author":"S Skovso","year":"2014","unstructured":"Skovso S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Investig. 2014;5(4):349\u201358.","journal-title":"J Diabetes Investig"},{"issue":"11","key":"1064_CR14","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.2337\/db11-0549","volume":"60","author":"Y Ti","year":"2011","unstructured":"Ti Y, et al. TRB3 gene silencing alleviates diabetic cardiomyopathy in a type 2 diabetic rat model. Diabetes. 2011;60(11):2963\u201374.","journal-title":"Diabetes"},{"issue":"2","key":"1064_CR15","doi-asserted-by":"publisher","first-page":"H656","DOI":"10.1152\/ajpheart.00726.2001","volume":"282","author":"DL Hickson-Bick","year":"2002","unstructured":"Hickson-Bick DL, et al. Palmitate-induced apoptosis in neonatal cardiomyocytes is not dependent on the generation of ROS. Am J Physiol Heart Circ Physiol. 2002;282(2):H656\u201364.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"1064_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s000180050067","volume":"53","author":"CP Reutelingsperger","year":"1997","unstructured":"Reutelingsperger CP, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. 1997;53(6):527\u201332.","journal-title":"Cell Mol Life Sci"},{"key":"1064_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-61779-860-3_5","volume":"887","author":"K Kyrylkova","year":"2012","unstructured":"Kyrylkova K, et al. Detection of apoptosis by TUNEL assay. Methods Mol Biol. 2012;887:41\u20137.","journal-title":"Methods Mol Biol"},{"issue":"7635","key":"1064_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nature20791","volume":"541","author":"G Pascual","year":"2017","unstructured":"Pascual G, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2017;541(7635):41\u20135.","journal-title":"Nature"},{"issue":"7","key":"1064_CR19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/ncb3551","volume":"19","author":"YJ Wang","year":"2017","unstructured":"Wang YJ, et al. Cholesterol and fatty acids regulate cysteine ubiquitylation of ACAT2 through competitive oxidation. Nat Cell Biol. 2017;19(7):808\u201319.","journal-title":"Nat Cell Biol"},{"issue":"9","key":"1064_CR20","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","volume":"79","author":"F Buffolo","year":"2022","unstructured":"Buffolo F, et al. Aldosterone as a mediator of cardiovascular damage. Hypertension. 2022;79(9):1899\u2013911.","journal-title":"Hypertension"},{"issue":"2","key":"1064_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1084\/jem.68.2.161","volume":"68","author":"GW Thorn","year":"1938","unstructured":"Thorn GW, Engel LL, Eisenberg H. The effect of corticosterone and related compounds on the renal excretion of electrolytes. J Exp Med. 1938;68(2):161\u201371.","journal-title":"J Exp Med"},{"issue":"2","key":"1064_CR22","first-page":"88","volume":"49","author":"H Selye","year":"1943","unstructured":"Selye H, Hall CE, Rowley EM. Malignant hypertension produced by treatment with desoxycorticosterone acetate and sodium chloride. Can Med Assoc J. 1943;49(2):88\u201392.","journal-title":"Can Med Assoc J"},{"key":"1064_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3181\/00379727-104-25782","volume":"104","author":"H Selye","year":"1960","unstructured":"Selye H. Protection by a steroid-spirolactone against certain types of cardiac necroses. Proc Soc Exp Biol Med. 1960;104:212\u20133.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"10","key":"1064_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med"},{"issue":"14","key":"1064_CR25","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"1064_CR26","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/cphy.c130044","volume":"4","author":"E Gomez-Sanchez","year":"2014","unstructured":"Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol. 2014;4(3):965\u201394.","journal-title":"Compr Physiol"},{"issue":"1","key":"1064_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12882-019-1348-4","volume":"20","author":"M Blankenburg","year":"2019","unstructured":"Blankenburg M, et al. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study. BMC Nephrol. 2019;20(1):171.","journal-title":"BMC Nephrol"},{"issue":"6","key":"1064_CR28","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cmet.2012.04.006","volume":"15","author":"IJ Goldberg","year":"2012","unstructured":"Goldberg IJ, Trent CM, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metab. 2012;15(6):805\u201312.","journal-title":"Cell Metab"},{"issue":"1","key":"1064_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","volume":"21","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol. 2022;21(1):232.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"1064_CR30","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","volume":"18","author":"D Montaigne","year":"2021","unstructured":"Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol. 2021;18(12):809\u201323.","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"1064_CR31","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1172\/JCI30335","volume":"117","author":"NH Son","year":"2007","unstructured":"Son NH, et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest. 2007;117(10):2791\u2013801.","journal-title":"J Clin Invest"},{"issue":"3","key":"1064_CR32","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1159\/000492091","volume":"48","author":"K Sikder","year":"2018","unstructured":"Sikder K, et al. High fat diet upregulates fatty acid oxidation and ketogenesis via intervention of PPAR-gamma. Cell Physiol Biochem. 2018;48(3):1317\u201331.","journal-title":"Cell Physiol Biochem"},{"issue":"7784","key":"1064_CR33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41586-019-1770-6","volume":"575","author":"M Fritsch","year":"2019","unstructured":"Fritsch M, et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 2019;575(7784):683\u20137.","journal-title":"Nature"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01064-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-023-01064-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01064-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T01:03:19Z","timestamp":1682730199000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-023-01064-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1064"],"URL":"https:\/\/doi.org\/10.1186\/s13098-023-01064-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2372964\/v1","asserted-by":"object"}]},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,29]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols related to animals were approved by the Shandong University Animal Care Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}